Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MUMPS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1986

Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.

A live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines have been applied to 887 and 148 children with various underlying diseases at the vaccine clinic of Osaka University Hospital between 1975 and 1985, respectively. Clinical reactions after mumps vaccination occurred in only 7 children (0.8%) and those after MRM vaccination in 28 children (19%), but their underlying diseases were not deteriorated by either vaccination. Clinical follow up study revealed that 2 of the 430 children immunized with mumps vaccine had contracted the disease during 7 year period and 2 of the 123 children immunized with MRM vaccine had contracted clinical mumps or rubella during 3 year period. The seroconversion rates after mumps vaccination were 70% and 61% by the hemagglutination inhibition (HI) test and neutralization (NT) test, respectively, while 94% by the fluorescent antibody to membrane antigen (FAMA) test. Those after MRM vaccination were 87% for measles, 96% for rubella by the HI test and 89% for mumps by the FAMA test. Serological follow up study revealed that antibodies elicited by mumps vaccination were sustained without substantial decline for at least 7 years. These results suggest that a live attenuated mumps and MRM vaccines are safe and effective in children with various underlying diseases.

Antibodies, Viral↗
PubMed1984

Antibody responses to mumps virus proteins in natural mumps infection and after vaccination with live and inactivated mumps virus vaccines.

Paired sera from 20 patients with acute mumps infection, 16 from persons vaccinated with live attenuated mumps virus vaccine, and 12 from persons vaccinated with formalin-inactivated virus vaccine were studied for mumps antibodies by single radial hemolysis (SRH), hemagglutination inhibition (HI), and by enzyme immunoassays (EIA) specific for whole virus, envelope glycoprotein, and nucleocapsid antibodies. Mumps patients had diagnostic rises in serum mumps antibodies in 90-100% of the cases depending on the method of assay. Vaccination resulted in seroconversion in 75-88% (live vaccine) and in 92% (inactivated vaccine) of the cases as detected by SRH or EIAs, whereas HI detected seroconversion only in 38% and 58% of the cases, respectively. Immunoprecipitation analyses revealed that all sera from mumps patients and nearly all postvaccination sera had antibodies against the main structural proteins of mumps virus. By immunoblotting, antibodies against denatured hemagglutinin-neuraminidase (HN) and fusion protein (F) were detected in 15-25% of mumps patients and persons vaccinated with live vaccine, whereas most postvaccination sera from those vaccinated with inactivated vaccine had HN (92%) and F (83%) protein antibodies, suggesting that antibodies against the denatured form of proteins are formed.

Antibodies, Viral↗
PubMed1998

[Wide spread inflammation of the parotid glands (mumps): underestimated disease. I. Epidemiology of the mumps and its medical meaning in Poland].

Mumps is commonly considered a "mild" infectious disease in children because death due to mumps is very rare. However, mumps causes a high rate of complications in young adults, and its burden should not be underestimated. Before the introduction of vaccine, mumps was a common infectious disease with high incidence rates which exceeded 100 per 100,000 population in most countries. Poland continues to belong to the group of countries, which do not use mumps vaccine. In Poland, the number of reported mumps cases per year ranges from 40,000 to 220,000, yielding an annual incidence rates of 110 and 570 per 100,000 population. It is estimated that each year in Poland, mumps causes 1000 cases of aseptic meningitis (range 400 to 2,200), 100 cases of encephalitis, 250 to 1375 cases of epidymo-orchitis in post-pubertal men, 50-275 cases of oophoritis in women. The age distribution of mumps cases is characteristic for a country that does not use mumps vaccine. For more that 20 years, the highest mumps incidence has occurred in children aged 5-9 years. In many countries the number of reported cases has declined significantly following the introduction of mumps vaccine, and in several countries the incidence has fallen to less than 1 per 100,000 population. Several countries using mumps vaccine have reported a shift in the age distribution of mumps cases, with an increased incidence in older children and young adults. Countries with high levels of coverage with measles-mumps-rubella (MMR) vaccine have nearly eliminated encephalitis associated with these diseases. A few countries using mumps vaccine have experienced relative resurgence of the disease, either due to incomplete vaccine coverage of certain age groups (USA) or problems with the long-term immunogenicity of mumps vaccine based on the Rubini strain (Portugal, Switzerland).

Adolescent↗
PubMed1986

Detection of specific immunoglobulin M to mumps virus in serum and cerebrospinal fluid samples from patients with acute mumps infection, using an antibody-capture enzyme immunoassay.

An immunoglobulin M (IgM) antibody-capture immunoassay using peroxidase-labelled mumps antibodies is described and its suitability for the practical diagnosis of acute mumps infection is evaluated. All 45 patients with confirmed mumps infection showed specific mumps IgM antibodies in their sera. Similarly, mumps IgM antibodies were detected in cerebrospinal fluid samples and sera from 12 patients with meningitis. Among these patients 8 had positive mumps virus isolates from the cerebrospinal fluid and 4 had not. Conversely, mumps IgM antibodies were detected neither in 418 serum samples from adult patients expected to be negative for mumps IgM, nor in 184 cerebrospinal fluid specimens from patients with various central nervous system symptoms, nor in sera from 10 patients with high levels of IgM-rheumatoid factor. Among 20 patients with respiratory illness caused by parainfluenza type-1 virus none showed an IgM mumps antibody response. In 99% of cases with acute mumps infection the IgM-ELISA gave a positive result in the first available serum samples most of which were negative for CF and mumps IgG antibodies. The virus proteins which take part in the IgM-ELISA test immune reaction are mainly the nucleoprotein and to a lesser extent the membrane protein. The IgM-ELISA method, which can be performed in 6 hours, offers a reliable, sensitive and rapid alternative to routine methods for the diagnosis of acute mumps infection.

Antibodies, Viral↗
PubMed1999

Mumps and mumps vaccine: a global review.

Mumps is an acute infectious disease caused by a paramyxovirus. Although the disease is usually mild, up to 10% of patients can develop aseptic meningitis; a less common but more serious complication is encephalitis, which can result in death or disability. Permanent deafness, orchitis, and pancreatitis are other untoward effects of mumps. Based on data reported to WHO up to April 1998, mumps vaccine is routinely used by national immunization programmes in 82 countries/areas: 23 (92%) of 25 developed countries, 19 (86%) of 22 countries with economies in transition (mainly the Newly Independent States of the former Soviet Union), and 40 (24%) of 168 developing countries. Countries that have achieved high coverage have shown a rapid decline in mumps morbidity. Furthermore, in many of these countries, mumps-associated encephalitis and deafness have nearly vanished. This review considers the disease burden due to mumps; summarizes studies on the immunogenicity, efficacy, and safety of different strains of mumps vaccine; and highlights lessons learned about implementing mumps immunization in different countries. Countries already using mumps vaccine should monitor immunization coverage and establish routine mumps surveillance with investigation of outbreaks. Where mumps is targeted for elimination, countries need to add a second dose of mumps vaccine for children, keeping in mind that the disease may still occur in susceptible adults.

Adult↗
PubMed1994

Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children.

Mumps-measles-rubella vaccination-induced antibody responses were studied in Type 1 diabetic children to find out the possible aberrations in mumps antibody responsiveness previously seen after natural mumps in Type 1 diabetic children. Mumps, measles, and rubella virus antibodies were studied in 364 newly diagnosed Type 1 diabetic subjects, their 240 non-diabetic siblings and 59 age- and sex-matched, unrelated, non-diabetic control subjects who all had received mumps-measles-rubella vaccine but had not had the respective infections. Sera were collected from all children at the time of the diagnosis of diabetes in the index case which was on average 2.5 years after the mumps-measles-rubella vaccination. The levels of IgG class mumps virus antibodies were lower in diabetic patients than in their non-diabetic siblings (p < 0.0005). This difference was most pronounced in males as male patients had significantly lower IgG mumps antibody levels than female patients. Rubella and measles IgG antibodies did not differ between patients and control subjects. The results are in accordance with previous studies suggesting a selective decrease in mumps antibody levels in Type 1 diabetic children. As the exposure to mumps virus had been exactly the same in all study groups, low mumps antibodies in diabetic children suggest decreased responsiveness rather than different number of past infections in these patients.

Adolescent↗
PubMed1986

Serological diagnosis of mumps and parainfluenza type-1 virus infections by enzyme immunoassay, with a comparison of two different approaches for detection of mumps IgG antibodies.

Two solid-phase enzyme-linked immunosorbent assays (ELISA) for detection of mumps IgG antibodies, viz., indirect ELISA and catching-antibodies (C.A.)-ELISA, are described and the results obtained with both assays are compared with each other and with the conventional complement-fixation (CF) test. In the indirect method, mumps antigens are used for coating the wells of the microtest plates, whereas in the C.A.-ELISA method mumps antigens are selectively bound to rabbit anti-mumps antibodies coated surfaces. A positive correlation was found between the optical density (O.D.) values given by both ELISA assays and CF-antibody titers. The ELISA assays showed improved sensitivity compared to the CF test, since 54% (C.A.-ELISA) and 33% (Indirect-ELISA) of additional positive reactions were detected by these assays. In terms of specificity, however, only the C.A.-ELISA was superior to CF, since significant rises of IgG-antibodies were detected only in paired sera of mumps patients. Conversely, when the indirect method was used significant IgG antibody rises were demonstrated in paired sera from mumps patients and in serum pairs of six patients with parainfluenza type-1 virus infection. With the CF test, heterologous antibodies responses were demonstrated in 2 of these patients. Absorption experiments of mumps sera with mumps and parainfluenza virus strains demonstrated that the IgG antibodies detected by the C.A.-ELISA are specific for mumps virus and therefore interference due to heterologous antibody responses were not observed. Results with purified mumps virus proteins demonstrated that the antigen-antibody reactions that partake in the C.A.-ELISA are mainly associated with the nucleoprotein antigen. Detection of IgG-antibodies to parainfluenza virus type-1 was assessed by ELISA (paraflu-T1-ELISA) using only the indirect approach. The results obtained with this assay showed improved sensitivity compared to a paraflu T1-CF test, since 47% of additional positive reactions were demonstrated by ELISA. In terms of specificity, however, heterologous antibody responses were detected by both the ELISA and the CF test in 4 out of 20 patients with mumps infections.

Antibodies, Viral↗
PubMed2002

High level expression of recombinant mumps nucleoprotein in Saccharomyces cerevisiae and its evaluation in mumps IgM serology.

To develop improved reagents for mumps serology a high-level yeast expression system was employed to produce recombinant mumps nucleoprotein (rNP). The rNP was purified by CsCl gradient centrifugation and yielded approximately 15 mg/l of yeast culture. Electron microscopy of the rNP revealed characteristic herring-bone structures. The electrophoretic mobility of rNP in yeast cells was similar to native NP in SDS-PAGE. Monoclonal antibodies to rNP reacted with native mumps virus nucleoprotein by immunofluorescence assay. A monoclonal antibody to native mumps virus NP reacted with rNP by Western blot assay. The rNP was investigated as antigen in an IgM capture enzyme immunoassay (EIA) using a horseradish peroxidase conjugate of monoclonal antibody to the rNP. Eighteen sera previously found to be positive by IgM capture radioimmunoassay (MACRIA) and 30 sera that were mumps IgM negative by MACRIA were tested by mumps IgM capture EIA. The results for the two test were concordant. In addition, 26 rheumatoid factor positive sera and 35 sera that were IgM positive for measles, rubella or parvovirus B19 were tested. Fifty-nine sera were negative by mumps IgM capture EIA but two sera collected from two infants 3 and 6 weeks after mumps, measles and rubella vaccination were positive. Mumps MACRIA confirmed these results. Compared to MACRIA the overall sensitivity was 100% (20/20) and specificity was 96.8% (30/31). The yeast expressed rNP was highly immunogenic and suitable for use in IgM capture EIA for the diagnosis of mumps.

Animals↗
PubMed2003

Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

GSK-MMR (Priorix) is a trivalent live attenuated measles, mumps and rubella (MMR) vaccine which contains the Schwarz measles, the RIT 4385 mumps (derived from the Jeryl Lynn mumps strain) and the Wistar RA 27/3 rubella strains. GSK-MMR as a primary vaccination demonstrated high immunogenicity in clinical trials in >7500 infants aged 9-27 months, and was as immunogenic as Merck-MMR (MMR II). However, antimumps seroconversion rates and geometric mean titres (GMTs) were significantly higher in infants receiving GSK-MMR compared with Berna-MMR (Triviraten trade mark ) recipients. Coadministration of GSK-MMR with a varicella vaccine (Varilrix; GSK-MMR/V) did not significantly affect the immunogenicity of GSK-MMR. A persistent immune response to GSK-MMR has been demonstrated in follow-up data from several randomised trials. GMTs for measles, mumps and rubella antibodies remained high in GSK-MMR recipients 1-2 years post-vaccination and were similar to those in Merck-MMR recipients. The immunogenicity of GSK-MMR was high, and similar to that of Merck-MMR, when used as a second dose in children aged 4-6 or 11-12 years who had received a primary vaccination with Merck-MMR in their second year of life. Although there are no protective efficacy data concerning the GSK-MMR vaccine to date, the rubella Wistar RA 27/3 rubella and Schwarz measles strains have well established protective efficacy; the new RIT 4385 mumps strain is expected to afford similar protection from mumps to that achieved with mumps vaccines that contain the Jeryl Lynn mumps strain (e.g. Merck-MMR). GSK-MMR was well tolerated as a primary or secondary vaccination, and in most clinical studies comparing GSK-MMR with Merck-MMR as a primary vaccination in infants, GSK-MMR was associated with significantly fewer local adverse events (e.g. pain, swelling and redness). The incidence of local adverse events with GSK-MMR, GSK-MMR/V or Berna-MMR was similar. GSK-MMR and Merck-MMR were associated with similar rates of fever, rash and parotid gland swelling, but Berna-MMR was associated with a lower incidence of fever. In conclusion, GSK-MMR is a highly immunogenic MMR vaccine with good tolerability. In clinical trials, the immunogenicity of GSK-MMR was similar to that of Merck-MMR, and the mumps component was more effective at eliciting seroprotection than that of Berna-MMR. Furthermore, GSK-MMR causes fewer injection-site adverse events than Merck-MMR. As such, GSK-MMR is an attractive alternative for immunisation against measles, mumps and rubella.

Child↗
PubMed1998

[Wide-spread inflammation of the parotid glands (mumps): an underestimated disease. II. Development, use, efficacy and safety of mumps vaccines].

Effective attenuated live virus mumps vaccines have been available for more than 30 years. Vaccine strains have been developed on various cell culture systems; the attenuated mumps virus strain most commonly used is the Jeryl Lynn strain. Various vaccines differ in their immunogenicity, efficacy and associated adverse events. It is estimated that the immunization coverage needed to block the transmission of mumps virus is at least 70%. Models indicate that low to moderate levels of mumps vaccine coverage may actually increase the number of susceptibles and the number of cases in older age groups. Benefit-cost analyses in a number of countries have found that the introduction of mumps vaccine is economically justifiable, as vaccination can avert the considerable medical and economic costs associated with mumps morbidity. Countries that do not immunize against mumps continue to register high mumps morbidity, and pay a high toll from neurological and other complications of mumps. Poland, which already has a high level of measles vaccine coverage, should make efforts to replace monovalent measles vaccine with trivalent measles-mumps-rubella (MMR) vaccine.

Adolescent↗
PubMed1998

[Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland)].

BACKGROUND: The number of mumps cases reported in Switzerland markedly increased from 1993 to 1995 although vaccination coverage against mumps had risen steadily since the national MMR immunization program was launched in 1987. In 1991, an estimated 80% of children 27 to 36 month-old were immunized against mumps. The purpose of the present study was to assess the hypothesis that the epidemic was the consequence of a low vaccine efficacy of the Rubini strain--a mumps vaccine strain that has been widely used in Switzerland. METHODS: Vaccine efficacy was assessed by measuring secondary attack rates among immunized and nonimmunized children 16 year-old or younger who wre family contacts of cases. RESULTS: From February 1993 to April 1996, Geneva pediatricians reported 283 primary cases of mumps and 63 secondary cases. Estimate of vaccine efficacy was equal to 6.3% (95% CI: -45.9; 39.8) for the Rubini strain, as compared to 73.1% (95% CI: 41.8; 87.6) for the Urabe Am 9 strain, and 61.6% (95% CI: 0.0; 85.4) for the Jeryl Lynn strain, two vaccine strains of mumps that had also been used in Geneva. CONCLUSION: Our study supports the hypothesis that the Rubini vaccine strain of mumps does not confer sufficient long-lasting protection against mumps.

Adolescent↗
PubMed1993

Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Childhood Diabetes in Finland Study Group.

A nationwide mumps-measles-rubella vaccination was introduced in 1982 in Finland to children aged 1.5 to 6 years and since then mumps has virtually disappeared in the country. We investigated whether this rapid epidemiological change had any impact on antibody activity against mumps virus in Type 1 (insulin-dependent) diabetic children or on the incidence of Type 1 diabetes in Finland. Two case-control series were collected before (series I and II) and three series after (series III-V) the introduction of the vaccination. IgA class mumps antibody levels were significantly higher in Type 1 diabetic children than in matched control children in the first two but not in the three later series. IgG class antibody levels were similar in patients and control subjects in the first two series but significantly lower in patients than in control subjects in the three later series. The overall incidence of Type 1 diabetes in 0-14-year-old children increased until 1987 but remained about the same during 1988-1990. In 5-9-year-old children no further increase in Type 1 diabetes was seen since 1985, whereas in 0-4-year-old children the incidence continued to rise until 1990. The results suggest that the elimination of natural mumps by mumps-measles-rubella vaccination may have decreased the risk for Type 1 diabetes in Finland; a possible causal relationship is substantiated by the observed concomitant decrease in mumps antibody levels in diabetic children. However, further studies are required to determine if the vaccine virus, like natural mumps, could trigger the clinical onset of Type 1 diabetes in young children.

Adolescent↗
PubMed2002

The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997.

BACKGROUND: Few data are available on the risk of aseptic meningitis following vaccination with the Leningrad-Zagreb (L-Z) strain of mumps vaccine. In 1997 the mumps vaccine was introduced into the state of Rio Grande do Sul in Brazil through mass vaccination with mumps-measles-rubella (MMR), targeting children aged 1-11 years. Five municipalities used exclusively MMR vaccine containing the L-Z strain of mumps. An outbreak of aseptic meningitis was observed shortly after the mass campaign. METHODS: To estimate the risk of aseptic meningitis associated with this strain, we analysed vaccination and meningitis case surveillance data from the selected municipalities. A case of vaccine-associated aseptic meningitis was defined as one with a pleocytosis of 10-1,500 leukocytes/ml and occurring within 15-35 days after vaccine receipt. RESULTS: We estimated a risk of 2.9 cases per 10,000 doses of L-Z administered, equivalent to 1 case per 3,390 doses administered. The overall risk of aseptic meningitis following the campaign was increased 12.2-fold (95% CI: 6.0-24.7) compared with the same period in 1995-1996. Following the mass campaign, the incidence of mumps declined 93% during 1998-2000. CONCLUSIONS: Vaccination with the L-Z strain of mumps vaccine as part of a mass campaign was associated with a significantly increased risk of aseptic meningitis. Decisions about type of mumps vaccine and mumps vaccination strategies must consider vaccine safety issues in addition to other criteria.

Brazil↗
PubMed1982

[Virologic diagnosis of mumps infection: a solid phase radioimmunoassay for the detection of mumps specific IgM antibodies (MACRIA)].

A solid phase radioimmunoassay for the detection of mumpsspecific IgM antibodies (MACRIA) is described. In 22 cases of clinically suspected mumps infections confirmed by conventional serological methods, IgM antibodies to mumps virus were detectable. On the other hand, no mumpsspecific IgM antibodies were present in 9 cases of suspected mumps that could not be confirmed by classical serology (seroconversion or significant titer rise in CFT or NT). Neither could IgM antibodies to mumps virus be detected in the sera of 19 rheumatoid factor positive patients nor in those of 20 healthy laboratory personnel. 20 patients from a rubella outbreak who had been found to be positive for antirubella IgM in a comparable MACRIA system showed no IgM response in mumps-MACRIA. In one case of mumps infection during pregnancy where mumps virus was isolated from the salivary glands by throat swab, IgM antibody response was delayed and markedly weaker than in all other patients with a positive IgM response. For this patient, who showed a significant titer rise in NT and seroconversion in CFT to mumps virus, the possibility of reinfection is discussed.

Antibody Specificity↗